A citation-based method for searching scientific literature

Alessandra Michelucci, Flavia Manzo Margiotta, Salvatore Panduri, Annalisa Tonini, Marco Romanelli, Riccardo Morganti, Agata Janowska, Valentina Dini. Dermatol Ther 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.
Matteo Megna, Angelo Ruggiero, Adriana Di Guida, Angela Patrì, Gabriella Fabbrocini, Claudio Marasca. Dermatol Ther 2020
22
100

Alopecia universalis improvement following risankizumab in a psoriasis patient.
F Martora, A Villani, S S Ocampo-Garza, G Fabbrocini, M Megna. J Eur Acad Dermatol Venereol 2022
3
100

The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience.
Angelo Ruggiero, Fabrizio Martora, Vincenzo Picone, Luca Potestio, Elisa Camela, Teresa Battista, Gabriella Fabbrocini, Matteo Megna. Clin Exp Dermatol 2022
5
100

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Andrew Blauvelt, Russel Burge, Gaia Gallo, Bridget Charbonneau, William Malatestinic, Baojin Zhu, Fangyu Wan, Benjamin Lockshin. Dermatol Ther (Heidelb) 2022
4
100


Safety of dupilumab in atopic patients during COVID-19 outbreak.
Maddalena Napolitano, Cataldo Patruno, Angelo Ruggiero, Mariateresa Nocerino, Gabriella Fabbrocini. J Dermatolog Treat 2022
21
100


Real-life experience of guselkumab in patients with psoriasis.
Igor Snast, Shany Sherman, Roie Holzman, Emmilia Hodak, Lev Pavlovsky. Dermatol Ther 2020
17
100

Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection.
M C Annunziata, A Patrì, A Ruggiero, A Di Guida, C Menicanti, V Greco, G Fabbrocini. J Eur Acad Dermatol Venereol 2020
11
100

A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
David Medina-Catalán, Pau Riera, Neus Pagès-Puigdemont, Montserrat Masip, Anna López-Ferrer, Eva Vilarrasa, Lluís Puig. Int J Clin Pharm 2022
2
100


Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study.
Marco Galluzzo, Lorenzo Tofani, Paolo Lombardo, Alessandra Petruzzellis, Dionisio Silvaggio, Colin Gerard Egan, Luca Bianchi, Marina Talamonti. J Clin Med 2020
29
100


Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
Ilenia Pantano, Daniele Mauro, Francesca Romano, Alessio Gambardella, Mario Valenti, Davide Simone, Daniela Iacono, Antonio Costanzo, Giuseppe Argenziano, Francesco Ciccia. Rheumatology (Oxford) 2022
6
100

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio,[...]. J Eur Acad Dermatol Venereol 2021
23
100

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna. Clin Exp Dermatol 2022
31
100


A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio,[...]. J Eur Acad Dermatol Venereol 2022
7
100

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Laura Calabrese, Marta Grimaldi, Gaia Moretta, Gianluca Pagnanelli, Ruslana Gaeta Shumak, Marina Talamonti, Lorenzo Tofani,[...]. Dermatol Ther 2022
9
100

A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.
E Sotiriou, K Bakirtzi, I Papadimitriou, A Tsentemeidou, P Eftychidou, V Eleftheriadis, A Lallas, D Ioannides, E Vakirlis. J Eur Acad Dermatol Venereol 2022
6
100

Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab.
Khalad Maliyar, Ashley O'Toole, Melinda J Gooderham. J Cutan Med Surg 2020
22
100

Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis.
Surjit Singh, Saurabh Singh, Abisha Thangaswamy, Pugazhenthan Thangaraju, Shoban Babu Varthya. Dermatol Ther 2021
8
100

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis.
Angelo Ruggiero, Gabriella Fabbrocini, Sara Cacciapuoti, Eleonora Cinelli, Lucia Gallo, Matteo Megna. J Clin Med 2021
12
100

Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Sascha Gerdes, Beate Bräu, Matthias Hoffmann, Bernhard Korge, Dariusch Mortazawi, Franca Wiemers, Sven Wegner, Yvonne Personke, Mario Gomez, Michael Sticherling. J Dermatol 2021
6
100

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini. J Dermatolog Treat 2022
14
100

Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study.
A-C Fougerousse, P-D Ghislain, Z Reguiai, F Maccari, J Parier, D Bouilly Auvray, G Chaby, V Pallure, J-L Schmutz, C Clément,[...]. J Eur Acad Dermatol Venereol 2020
22
100

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.
Spyridon Gkalpakiotis, Petra Cetkovska, Petr Arenberger, Tomas Dolezal, Monika Arenbergerova, Barbora Velackova, Jorga Fialova, Martina Kojanova. Dermatol Ther (Heidelb) 2021
13
100

Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.
Claudio Marasca, Angelo Ruggiero, Matteo Megna, Maria Carmela Annunziata, Gabriella Fabbrocini. J Dermatolog Treat 2022
22
100

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
Marco Galluzzo, Marina Talamonti, Arnaldo Cioni, Virginia Maffei, Ruslana Gaeta Shumak, Lorenzo Tofani, Luca Bianchi, Elena Campione. J Clin Med 2022
6
100

Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness.
Raquel Rivera-Díaz, Mar LLamas-Velasco, Mercedes Hospital, Isabel Martín, Ofelia Baniandrés, Diana Ruíz-Genao, Pablo de la Cueva, Carmen García-Donoso. Expert Opin Biol Ther 2022
2
100

Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series.
Noha Mohammed Dawoud, Maha Bedair El Badawy, Hala Subhi Al Eid, Moataz M Abdel Fattah. Indian J Dermatol Venereol Leprol 2022
3
100

Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E et al.
M Megna, L Potestio, L Gallo, G Caiazzo, A Ruggiero, G Fabbrocini. J Eur Acad Dermatol Venereol 2022
30
100

Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Luca Mastorino, Sara Susca, Matteo Megna, Niccolò Siliquini, Pietro Quaglino, Michela Ortoncelli, Gianluca Avallone, Marco Rubatto, Gabriella Fabbrocini, Paolo Dapavo,[...]. Dermatol Ther 2022
9
100

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Matteo Megna, Nello Tommasino, Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Noto, Gabriella Fabbrocini, Lucia Genco. J Dermatolog Treat 2022
11
100

A case of erythrodermic psoriasis successfully treated with guselkumab.
Matteo Megna, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini, Claudio Marasca. Dermatol Ther 2020
22
100

Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Giacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, Mauro Bavetta, Clara De Simone, Dario Graceffa, Claudio Bonifati, Sara Faleri, Domenico Giordano, Marco Mariani,[...]. Dermatol Ther 2022
3
100


Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
Jia-Yi Zhuang, Jin-Sheng Li, Yuan-Qiu Zhong, Fang-Fei Zhang, Xin-Ze Li, Hang Su, Ze-Qiao Zhang, Xiao-Hua Wang, Yong-Feng Chen. Dermatol Ther 2021
1
100

Psoriasis Pathogenesis and Treatment.
Adriana Rendon, Knut Schäkel. Int J Mol Sci 2019
453
100

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi. Drugs Context 2021
10
100

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.
Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, Elisa Camela, Angelo Ruggiero. J Dermatolog Treat 2022
28
100



Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
141
100

Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients.
G Malara, C Trifirò, A Bartolotta, C Giofré, G D'Arrigo, A Testa, A De Lorenzo, G Tripepi. Eur Rev Med Pharmacol Sci 2021
5
100

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna. J Am Acad Dermatol 2021
25
100

May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?
Claudio Marasca, Angelo Ruggiero, Maddalena Napolitano, Gabriella Fabbrocini, Matteo Megna. Med Hypotheses 2020
21
100

Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al.
L Potestio, L Genco, A Villani, C Marasca, G Fabbrocini, L Fornaro, A Ruggiero, F Martora. J Eur Acad Dermatol Venereol 2022
13
100

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis.
Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H Hagman, Rauno Harvima, Johanna Höök-Nikanne,[...]. Acta Derm Venereol 2022
3
100

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
296
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.